Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.54 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.54 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.54 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.54 |
| ▸ | GJB2 | P29033 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 6/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15975382 | 0.93 | SSTR1 (0.53) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13130007 | 0.93 | GJB2 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL15975388 | 0.91 | GJB2 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13129827 | 0.91 | GJB2 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13129826 | 0.91 | GJB2 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13129789 | 0.91 | GJB2 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13129876 | 0.91 | GJB2 (0.50) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL13129935 | 0.89 | GJB2 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14428879 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14428868 | 0.88 | SSTR1 (0.60) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | ST3GAL3, SI, STT3A | SSTR1 1053/4885SSTR2 2046/4885SSTR4 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.